Asabys Announces a New Life Sciences Fund Following Its Selection in the CDTI and EIF Innvierte Deep Start Initiative - Asabys Partners

READ THIS NEWS IN SPANISH

• Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech companies in Spain.
• Asabys has been selected as a fund manager in the Innvierte Deep Start initiative, promoted by CDTI in collaboration with the European Investment Fund (EIF), within the framework of Spain’s National Deep Tech Strategy 2026–2030.

Asabys Partners, a leading life sciences investment firm, has been selected in the Innvierte Deep Start initiative, promoted by the Centre for the Development of Technology and Innovation (CDTI) in collaboration with the European Investment Fund (EIF), further strengthening its position as a key player in the European healthcare venture capital ecosystem.

In this context, Asabys is launching Asabys Innvierte Tech Transfer FCRE, a new fund that could reach a size of €120 million, aimed at fostering the creation and development of innovative companies in the life sciences sector, with a particular focus on biotechnology and medical technologies.

This new vehicle marks the beginning of a new strategic vertical for Asabys. The firm currently manages two additional funds within its core strategy, including its Sabadell Asabys II fund (vintage 2023), which already includes 10 portfolio companies and remains actively engaged in identifying new investment opportunities across Spain and Europe. In addition, Asabys participates in the management of the Alta Life Sciences fund following the integration of the firm into Asabys in October 2025.

Asabys Innvierte Tech Transfer FCRE is managed by a dedicated team of seven professionals, including three partners: Emilio Erazo-Fischer, Montserrat Vendrell, and a third partner whose identity is currently confidential. The fund will also benefit from the support of the broader Asabys team, which currently consists of 18 professionals and is expected to grow to 20 before the summer.

Asabys Partners manages close to €400 million in assets under management and has 23 portfolio companies. Since its founding in 2018, the firm has worked closely with universities, hospitals, and research centers. This collaboration has enabled the creation of academic spin-offs such as Ona Therapeutics, Inbrain Neuroelectronics, Nuage Therapeutics, OrikineBio, and ALLOX, consolidating Asabys’ position as a key partner in technology transfer in Spain.

The new fund launches with an active pipeline of opportunities under evaluation and development that maximize the use of disruptive technologies such as artificial intelligence, supercomputing, synthetic biology, new materials, and novel therapeutic modalities. The fund will contribute to attracting and training talent, promoting the creation of highly qualified jobs, and building world-class teams. All with a clear ambition: to make science the future of Spain.

Clara Campàs, Managing Partner at Asabys, commented: “Spain is home to world-class science that historically has not received sufficient funding to be transformed into solutions that impact people’s health.” Meanwhile, partners Montserrat Vendrell and Emilio Erazo-Fischer added respectively: “With this fund, we want to help close that gap by working closely with researchers and institutions to turn this knowledge into successful companies and value for society” and “As investors specialized in life sciences, with a team that combines strong scientific expertise, we are passionate about collaborating closely with the research community to advance cutting-edge therapeutic innovations and bring them closer to patients with significant unmet medical needs.”

About Asabys Partners

Asabys Partners is a Barcelona-based venture capital firm specialized in healthcare and life sciences innovation, including biotechnology, medical technology, and digital health. Founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, the firm is backed by Alantra, with Banco Sabadell as anchor investor. Asabys aims to support highly innovative and transformative technologies addressing unmet medical needs. The firm manages over €400 million in assets and has 23 portfolio companies. Asabys positions itself not only as an investor but also as an active and collaborative partner to its portfolio companies, with the goal of translating disruptive science into tangible outcomes for patients.